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131Transarterial treatment of congenital renal
arteriovenous ﬁstulas
Naiem Nassiri, MD, Yuriy Dudiy, MD, Alﬁo Carroccio, MD, and Robert J. Rosen, MD, New York, NY
Objective: Congenital renal arteriovenous ﬁstulas (CRAVF) represent a distinct clinical entity with characteristic hemo-
dynamic and angiographic features. Treatment is warranted given potential for growth with renal and hemodynamic
compromise. We report our experience in a rare series of treated symptomatic CRAVFs.
Methods: Over a 10-year period, patients treated for symptomatic CRAVFs (no history of predisposing renal pathology,
instrumentation, neoplasm, or trauma) were retrospectively investigated for clinical presentation, imaging features,
treatment outcomes, and complications. Technical success included delivery of embolic agent with complete obliteration
of ﬁstula. Clinical success included resolution of symptoms and freedom from recurrence and/or reintervention. Renal
parenchymal loss was estimated by postembolization angiography and categorized as 0%, <25%, 25%-50%, or >50%.
Results: Twenty-ﬁve patients were referred with a presumptive diagnosis of intraparenchymal renal artery aneurysms. Of
these, 10 had true intrarenal aneurysms, three had angiomyolipomas, and 12 had CRAVFs (mean age, 54; range,
29-71 years; eight women). Presenting symptoms included hematuria (eight gross, eight microscopic), refractory
hypertension (diastolic blood pressure $90 mm Hg despite three or more medications; n[ 6), ﬂank pain (n[ 8), high-
output state (HOS; featuring tachycardia and jugular venous distention; n [ 3), and ﬂank bruit (n [ 1). Deﬁning
angiographic features included a high-ﬂow AVF fed by a single, enlarged intrarenal branch shunting into an aneurismal
draining vein, occasionally featuring a calciﬁed rim (four patients). All patients underwent transarterial embolization with
coils (n[ 5), coils and n-butylcyanoacrylate (n[ 3), detachable balloons (n[ 2), or Amplatzer plugs (n[ 2). Technical
success was 100%. Hematuria, tachycardia, jugular venous distension, pain, and bruit resolved in all. Hypertension
improved in four of six patients (required less than three medications postembolization). Complications included post-
embolization syndrome in nine patients. Parenchymal loss was limited to <25% and observed in ﬁve patients without
development of acute kidney injury or worsening hypertension. There were no recurrences or reinterventions at a mean
follow-up of 55 months (range, 5-96 months). There was one death at 8 years follow-up from intercurrent coronary
disease in a patient without high-output state.
Conclusions: With greater awareness and accurate diagnosis, effective and durable transarterial treatment of CRAVFs can
be safely performed. (J Vasc Surg 2013;58:1310-5.)Arteriovenous malformations (AVMs) are pathologic confused with other more common pathologies such as
connections between arteries and veins anywhere upstream
of capillary level. These focal failures of embryologic
vascular development can progress into either simple,
ﬁstula-like connections between a single artery and vein or
a complex nidus of numerous, dilated, tortuous channels
(Fig 1). Within the renal circulation, the majority (>75%)
of AVMs are acquired as a result of iatrogenic injury
(commonly percutaenous renal biopsy procedures), trauma,
or neoplastic processes.1-13 With an autopsy-estimated inci-
dence of 0.04% and approximately 200 cases ever reported,
primary or congenital renal AVMs are extremely rare but
likely underdiagnosed for several reasons.2,13-17
First, they can be asymptomatic lesions found inciden-
tally on imaging studies. Once identiﬁed, they tend to bethe Lenox Hill Heart and Vascular Institute of New York, North
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0intrarenal aneurysms or neoplastic processes. Lastly, the
nomenclature used to describe these lesions has been
inconsistent in the case reports and small case series avail-
able across the literature.11,12
Once discovered, they warrant lifelong surveillance,
given the potential for growth and development of ﬂank
pain, renal vein and systemic hypertension, hematuria,
high-output cardiac failure, and distal renal ischemia.
Here, we present our diagnostic and therapeutic approach
in a rare series of patients with symptomatic congenital
renal arteriovenous ﬁstulas (CRAVF) e referred to as
cavernous renal AVMs across the literature.11,12 Increased
awareness of CRAVF as a distinct clinical entity with a char-
acteristic angioarchitecture and hemodynamic proﬁle can
lead to prompt diagnosis and effective treatment.METHODS
We retrospectively reviewed our prospectively main-
tained database of consecutive patients with symptomatic
CRAVFs over a 10-year period. All patients referred to
our institution for evaluation and treatment of symptom-
atic, intrarenal aneurysms had undergone contrast-
enhanced computed tomography (CT) at the time of
referral. After the initial clinical consultation, deﬁnitive
diagnosis was made by transcatheter angiography. Those
Fig 1. Arteriovenous malformation (AVM) featuring a nidus typically seen in extremity lesions (A). Arteriovenous
ﬁstula (AVF) featuring single arterial feeder with branches shunting into and aneurismal draining vein (B). The latter is
more commonly found in the pulmonary circulation in patients with hereditary hemorrhagic telangiectasias (HHT) or
congenital renal arteriovenous ﬁstulas (CRAVFs).
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rial embolization at the time of diagnostic angiography as
outlined below. Treated patients were observed overnight
and discharged the following day. Clinical follow-up was
scheduled at 1, 6, and 12 months, and annually thereafter.
Follow-up imaging consisted of CT scans at 1 month,
12 months, and annually thereafter.
Presenting symptoms, imaging features, angiographic
ﬁndings, interventional techniques, and clinical outcomes
including symptom resolution, lesion recurrence, reinter-
ventions, and complications were recorded. Technical
success was deﬁned as successful delivery of the embolic
agent with complete obliteration of the ﬁstula. Clinical
success was deﬁned as resolution of the presenting symp-
toms and freedom from recurrence and/or reintervention.
Renal parenchymal loss was estimated by postembolization,
multi-view angiography and categorized as 0%,<25%, 25%-
50%, or >50%. National Kidney Foundation criteria for
acute kidney injury (AKI) were used to assess kidney
function perioperatively and during follow-up.18
Technical details. All interventions were performed in
the catheterization suite under general anesthesia to maxi-
mize patient comfort, compliance, and imaging precision.
Arterial access was obtained through the common femoral
artery using the micropuncture technique and a 5-Fr short
sheath. A 5-Fr pigtail catheter was advanced into the aorta
at the L1 level for ﬂush aortography (Fig 2). Selective
catheterization of the main renal artery on the symptomatic
side was performed using a 5-Fr Cobra Catheter (Cook
Medical, Bloomington, Ind) and an appropriately-shaped
guide catheter or sheath. Selective angiography was then
performed in multiple views to accurately delineate the
location and anatomy of the AVF, including the size and
location of the feeding artery, its branches, and the drain-
ing vein (Fig 3, A and B). Next, superselective catheteri-
zation of the feeding arterial branch was performed either
via the same 5-Fr diagnostic catheter or through a coaxialmicrocatheter system (Renegade; Boston Scientiﬁc, Fre-
mont, Calif; Fig 3, C).
Once the angioarchitecture was adequately deﬁned,
systemic anticoagulation was administered to maintain an
activated clotting time $250 seconds. Transarterial embo-
lization of the feeding artery and the ﬁstula was performed
using proximal occluding devices. These included ﬁbered
coils (both macro- and microcoils), detachable balloons
(no longer available in the U.S.), or Amplatzer plugs
(AGA Medical, Golden Valley, Minn; Fig 4).
In these extremely high-ﬂow shunts, which reside in
a low-resistance vascular bed and are exposed to systemic
arterial pressures, a rapidly polymerizing adhesive such as
n-butylcyanoacrylate (n-BCA) was used occasionally to
form an instantaneous, voluminous cast once injected into
the ionic medium of blood. This cast was formed around
a previously deployed proximal occluding device (giant
framing coils or plugs) for maximal seal and closure of the
ﬁstula.Wepreparedn-BCA in a 1:1 solutionwith radiopaque
ethiodized oil to facilitate visualization during infusion,
thereby minimizing risk of nontarget embolization.
In situations where the extremely high-ﬂow shunt
precluded safe deployment of plugs or coils, transarterial
ﬂow control techniques were utilized. These included
staged deployment of detachable giant framing coils
(Azur; Terumo Medical Corporation, Somerset, NJ) to
serve as a stable nest onto which a cast of n-BCA or
multiple detachable microcoils (Azur; Terumo Medical
Corporation) could be deployed for maximal seal and
closure of the ﬁstula. Another ﬂow control technique
involved the use of occlusion balloon catheters (Berenstein
Occlusion Balloon Catheter; Boston Scientiﬁc) to reduce
ﬂow through the shunt (Fig 5). Microcatheter delivery
systems were then delivered coaxially through these
occlusion balloon catheters and used for safe deployment
of detachable microcoils and/or n-BCA adhesive with
minimal risk of nontarget embolization.
Fig 2. Flush aortography demonstrates enlarged ipsilateral renal artery (black arrow) (A and B), poor parenchymal
visualization compared with nonaffected side, an aneurismal draining vein (white arrow), and early detection of contrast
within an enlarged vena cava (white star). Note the presence of bilateral congenital renal arteriovenous ﬁstula
(CRAVFs) in a patient with horseshoe kidney (C).
Fig 3. Selective (A and B) and superselective (C) renal arteriography demonstrating a dilated, tortuous arterial feeder
(A and B) (black arrow) shunting into a rapid-ﬁlling aneurismal vein (white arrow).
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chymal viability were evaluated by multi-view angiography.
RESULTS
Over a 10-year period, 25 patients were referred for
selective renal angiography after CT scan had yielded
a tentative diagnosis of intrarenal aneurysms. Of these, 10
were found to have true intrarenal aneurysms, three had
renal angiomyolipomas, and 12 had CRAVFs (four men;
mean age, 54 years [range, 29-71 years]). There was no
history of predisposing renal pathology, instrumentation,
or trauma. Presenting signs and symptoms included hema-
turia (n ¼ 8), refractory hypertension (diastolic blood pres-
sure $90 mm Hg despite three or more medications; n ¼
6), ﬂank pain (n ¼ 8), high-output state (HOS; featuring
tachycardia and jugular venous distention with dyspnea
on exertion; n ¼ 3), and ﬂank bruit (n ¼ 1). Serum creat-
inine was #1.0 mg/dL in all patients prior to intervention.
In all 12 patients, angiography demonstrated a high-ﬂow
AVF fed by a single, enlarged arterial branch shunting
into an aneurismal draining vein. The draining veinoccasionally featured a calciﬁed rim (n ¼ 4). There was
no angiographic evidence of atherosclerotic, vasculitic, or
ﬁbrodyplastic lesions. There was one case of bilateral
CRAVFs in a patient with a horseshoe kidney (Fig 2, C).
All other lesions were unilateral and more commonly on
the right side (n ¼ 7). Technical success was 100%. Coils
alone were used in ﬁve, coils and n-BCA were used in
three, detachable balloons were used in two, and Amplat-
zer plugs (AGA Medical) were used in two patients (Fig 4).
Hematuria, tachycardia, jugular venous distention,
dyspnea on exertion, pain, and bruit resolved in all. Hyper-
tension improved in four of six patients (required less than
three medications postembolization). Complications
included postembolization syndrome (consisting of low-
grade fever [maximum temperature of 101F] and tran-
sient, self-limited, postprocedural ﬂank discomfort) in
nine patients. Estimated parenchymal loss limited
to <25% occurred in ﬁve patients (Fig 6). There was no
incidence of AKI or worsening hypertension periopera-
tively or during follow-up. There were no other episodes
of nontarget embolization or late device migration. There
Fig 4. Completion angiography after coils (A), n-butylcyanoacrylate (n-BCA) cast (B), and Amplatzer vascular plug II
(C) embolization (black arrow) of the arteriovenous ﬁstula (AVF).
Fig 5. Balloon-ﬂow control of a renal arteriovenous ﬁstula (AVF). Fig 6. Digital subtraction angiography following glue-
embolization reveals successful elimination of the shunt with
approximately <25% renal parenchymal loss at the lower pole.
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of 55 months (range, 5-96 months). There was one death
at 8-year follow-up from intercurrent coronary disease in
a patient without HOS.
DISCUSSION
Abnormal shunting of blood from arteries to veins
upstream of capillary level can either be acquired or congen-
ital. Within the congenital category, two angioarchitectural
varieties exist e AVMs and AVFs. AVMs are typically
comprised of multiple contributing arteries feeding
a complex nidus that is drained by an equally complex
network of tortuous draining veins. AVFs are less frequent
and less commonly congenital. Two examples of a congenital
AVF are those found in the pulmonary circulation in patients
with hereditary hemorrhagic telangiectasias and CRAVFs.They are typically isolated anatomically and involve a simple
connection between a single, enlarged, and often tortuous
feeding artery and an aneurismal draining vein. Within the
renal circulation, the terms cirsoid and cavernous have
been used to describe AVMs and AVFs, respectively.4,9,11,12
Given the pioneering classiﬁcation scheme described by
Mulliken and Glowacki and the subsequent criteria set forth
by the International Society for Study ofVascular Anomalies,
these terms have largely been abandoned and their use in
describing vascular anomalies is discouraged.19-21
CRAVFs represent only a small minority of all renal
vascular anomalies (<3%). Symptoms, if present, are not
speciﬁc, clinically mimicking other more common renal
Fig 7. Computed tomography angiography (CTA) demonstrating a dramatically aneurismal draining vein in a patient
with CRAVF. This was initially diagnosed as a renal artery aneurysm at an outside facility (A). Postembolization CT
scan (different patient) at 1 month (B) and 12 months (C) demonstrates complete devascularization and gradual
shrinkage of the draining vein, which featured a rim of calcium (B).
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and parapelvic cysts.1,2,7,22 Therefore, a greater degree of
clinical awareness among referring physicians and treating
specialists is warranted for accurate diagnosis. Associated
symptoms can include an HOS, refractory hypertension,
hematuria (gross or microscopic), abdominal pain, and
ﬂank bruits. CT, magnetic resonance imaging (MRI),
ultrasound, and, less commonly, intravenous pyelography
(IVP), or combinations thereof, are common screening
modalities.2,4,19 It is not uncommon that in the absence
of a high-degree of suspicion, these imaging modalities
fail to provide an accurate diagnosis of a CRAVF, as was
the case in the current series of patients prior to referral
for angiographic evaluation. As such, transcatheter angiog-
raphy remains the gold standard for diagnosing CRAVFs.
Nevertheless, as most CRAVFs are incidentally discov-
ered, awareness of common imaging features is essential.
Plain radiography has a limited role as a screening modality
although occasionally a rim of calcium can be detected.
This is neither sensitive nor speciﬁc. Contrast-enhanced
CT is arguably the most commonly used imaging modality
for detection of renal vascular anomalies, although distinc-
tion between a true AVF and an intrarenal aneurysm on
CT scan remains difﬁcult.2,19 It does, however, allow further
delineation of adjacent anatomy and associated lesions and
may help rule out other potential diagnoses (Fig 7). The
characteristic feature of a high-ﬂow renal AVM on
contrast-enhanced MRI is a low-intensity signal or a ﬂow
void within an aneurismal structure on T2-weighted images.
Given the abundance of nonvascular renal lesions with low-
intensity signals on MRI such as parapelvic cysts, the speci-
ﬁcity of MRI in identifying these renal anomalies remains
limited. In the authors’ experience, both CT and MRI are
best used as follow-up imaging modalities in patients who
have undergone treatment. The gold-standard imaging
modality for studying renal vascular anomalies is conven-
tional transcatheter angiography. It is the most accurate
means of delineating the associated vascular architecture
and allows concomitant catheter-based intervention, the
efﬁcacy of which can immediately be conﬁrmed on comple-
tion angiography.
Though CRAVFs structurally mimic other congenital
AVFs (such as the pulmonary lesions in hereditaryhemorrhagic telangiectasias), blood ﬂow and pressures
through CRAVFs are drastically higher, owing to a much
lower-resistance vascular bed demanding nearly 20% of
the cardiac output. One common manifestation of this
phenomenon is the dramatic aneurismal dilatation of the
draining vein, which may initially be misdiagnosed as a giant
renal artery aneurysm. The high ﬂow and low resistance
can result in a clinically signiﬁcant high output cardiac
state, a well-described phenomenon that is rarely encoun-
tered in AVMs present in other vascular beds.14 In the
current series, we encountered a 33% rate of high-output
cardiac state. Deﬁnitive treatment was promptly achieved
in all after initial transarterial embolization without recur-
rence over the follow-up period. As such, cure can be
achieved with macroscopic occlusive devices such as coils,
plugs, and detachable balloons.
As blood ﬂow through these lesions is torrential and
the intrinsic vascular resistance is low, there is an increased
risk of loss of the embolic device into the pathologically
dilated inferior vena cava and, ultimately, the pulmonary
circulation. To circumvent this, a combination of maneu-
vers may be necessary, including balloon ﬂow control, giant
framing coils, and in some cases, a rapidly polymerizing
adhesive to form an instantaneous cast with minimal risk
of reﬂux. Careful evaluation of the angioarchitecture and
hemodynamics of the ﬁstula and thorough knowledge of
the mechanical properties and in vivo behavior pattern of
utilized embolic devices can minimize the risk of device
migration and pulmonary embolization. We did not
encounter any device migration complications in this series.
The estimated <25% parenchymal loss is attributed to
inevitable embolization of arterial branches that share blood
supply with the artery feeding the ﬁstula and/or occasional
nonvisualization of a distal segmental branch. However, it
must be noted that chronic external compression of the renal
parenchyma by the enlarged feeding artery and/or the
aneurismal draining vein can contribute to parenchymal
compromise. Devascularization of the high-ﬂow shunt
unmasks this area of chronic compression, which can be
mistaken for nontarget embolization. Nevertheless, this
minimal loss of parenchymaewhile merely a visual estimate
based on completion angiography e does not appear to
have an effect on overall kidney function, particularly since
JOURNAL OF VASCULAR SURGERY
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nated promptly following embolization. As such, we have
found more rigorous methods of calculating the exact
volume of parenchymal loss (eg, renal scintigraphy with
CT volumetric analysis) to be extraneous and costly without
adding any further clinically valuable information. We
would, however, recommend these calculations be per-
formed if signiﬁcant parenchymal loss accompanied by AKI
or worsening renovascular hypertension is encountered.
Recently, several studies have provided remarkable
insight into the pathogenesis of high-ﬂow vascular malfor-
mations on a cellular and molecular level by demonstrating
upregulation of endothelial notch signaling system activity
in rats with brain AVMs.23,24 Furthermore, it has been
shown that down-regulation of Notch activity can facilitate
regression of these AVMs with conversion of large-caliber,
high-ﬂow AV shunts into capillary-like vessels.25 Future
AVM therapies may target these complex biomolecular
processes. For now, transarterial embolization can provide
safe, effective, and durable result with minimal morbidity.
CONCLUSIONS
CRAVFs represent a small minority of all renal vascular
anomalies (<3%). Diagnosis is based on transcatheter angi-
ography for delineation of associated vascular architecture.
Treatment has evolved over the years from total or partial
nephrectomy and branch vessel ligation to minimally inva-
sive, superselective, transarterial embolization at the time of
angiographic diagnosis. Though surgery is still warranted
to resect associated neoplastic lesions in acquired renal
AVFs or to treat rare refractory cases, our experience
with minimally invasive therapy has been widely successful
as no patient has required salvage surgical or repeat endo-
vascular intervention. Lifelong surveillance is required and
patient compliance, therefore, is essential.
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